Please login to the form below
simvastatin
This page shows the latest simvastatin news and features for those working in and with pharma, biotech and healthcare.
CETP inhibitor class finally dies as Merck abandons anacetrapib
ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.
Latest news
-
Merck & Co's anacetrapib data fails to generate much excitement
selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
-
FDA panel rejects cardiovascular outcomes claim for Vytorin
IMPROVE-IT involved 18, 000 high-risk patients with acute coronary syndromes (ACS) - including unstable angina and heart attacks - and compared Vytorin (ezetimibe and simvastatin) to simvastatin alone for their ability ... median seven-year follow-up
-
Merck hopes for another Keytruda with new immunotherapy deal
But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
-
Relief as study finds no cardiovascular risk with Januvia
Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
-
Merck's ezetimibe has 'modest' benefit when added to statins
The IMPROVE-IT trial was designed to compare the effects of Vytorin (simvastatin and ezetimibe) versus Zocor (simvastatin) on cardiovascular complications and death in 18, 000 post-ACS patients and got
More from news
Approximately 4 fully matching, plus 53 partially matching documents found.
Latest Intelligence
-
Rise of generic medicines in Portugal
Pedro Pita Barros, professor of economics and Nova School of Business and Economics, told PME: “ Patients have largely benefited from price decreases (for example, simvastatin dropped from above 50 for a ... Generics bestsellers in volume. Simvastatin.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
